A clinical trial examining the effect of a cannabis-derived treatment on people with type two diabetes has produced encouraging results.
Med7 and HempCo carried out a human clinical study looking at the effect of its full spectrum hemp oil, Hempzorb81, on people with the condition.
The placebo-controlled study on 150 patients found it helped participants lose weight and lower their A1C levels, the sugar-linked haemoglobin in blood that becomes too high in people with diabetes.
Patients lost an average of 14lbs and reduced their waistlines by four inches over the course of the six month study.
The research was carried out with funding support from the National Institutes of Health, an arm of the US Department of Health.
Type two diabetes is one of the most pressing health challenges facing the world, with the number of people living with the condition continuing to rise due to obesity rates.
A 2018 report by the International Diabetes Federation found 58 million people have the condition in Europe, contributing to 477,000 deaths.
The report calculated diabetes-related health interventions cost the continent more than £126bn every year.
Paul Murray, CEO of HempCo, said: “A naturally occurring whole plant extract with multiple cannabinoids and other natural components can have strong entourage effects on cannabinoid receptors if they can get into the blood stream effectively.
“These studies should give consumers and providers confidence that there are hemp products containing CBD that are backed by human clinical studies.”
MediPahrm completes cannabis extract delivery to Germany’s Vayamed
MediPharm has announced another GMP cannabis extract delivery to Germany.
MediPharm Labs has completed its medical cannabis extract to German-based Vayamed.
The company says the export is a key milestone in its goal of leveraging its pharmaceutical GMP licenses to increase consistent international medical sales. The extract has been shipped to Vayamed from the Company’s GMP facility located in Victoria, Australia.
Warren Everitt, CEO Asia Pacific, MediPharm Labs, commented: “As a pharmaceutical company specialising in precision-based cannabinoids MediPharm Labs continues to execute on delivering to its international partners.
“Making the deliveries to a leading company like Vayamed shows not only the demand for our quality products but the ability to navigate the complex regulations of international medical cannabis trade.
“It further demonstrates the value provided by our Australian business, which is already becoming a key asset for the Company as it continues to ship GMP product to a growing international market.”
“MediPharm Labs convinced us with a high level of product competence and a company philosophy that fits perfectly to our portfolio strategy and with the brand vision of Vayamed: Medicine from Nature – customised for patients,” added Thimo Schmitt-Lord, director of market development and sector innovation at Vayamed.
MediPharm said that it will be completing additional deliveries to Vayamed under the strategic partnership agreement, assisting them in providing more access to medical cannabis for German medical patients.
ASTM launches new international cannabis subcommittee
The subcommittee will be aimed at supporting the exchange of information in the global industry.
ASTM International’s cannabis committee has launched a new subcommittee in order to ‘facilitate dialogue’ in the global industry.
The subcommittee will be aimed at supporting the exchange of cannabis information and knowledge between global policymakers, regulators, scientists, and the general public.
Recently, at the request of the US Senate, the cannabis committee’s executive subcommittee provided public comment on the proposed Cannabis Administration and Opportunity Act.
The subcommittee shared key information on ASTM International’s cannabis efforts, including, the history and scope of the cannabis committee, definitions of cannabis terms and published standards related to cannabis facilities.
ASTM International is a not-for-profit, international standards organisation that develops voluntary consensus standards for a wide range of materials, products, systems, and services.
In 2017, it formed the ASTM Committee D37 on Cannabis with a group of industry leaders, to begin developing international standards for cannabis.
“With a patchwork of regulations across state, federal, and international levels, this subcommittee will be valuable to industry and government stakeholders as a means to collaborate,” commented David Vaillencourt, current chair of the new government liaison subcommittee.
“It’s really going to facilitate dialogue that will be key as we look ahead to a global marketplace in the coming years.”
Economic sovereignty for indigenous farmers through cannabis cultivation
The NACA has signed three groundbreaking agreements which support the use of tribal farmland for cannabis cultivation.
The Native American Cannabis Alliance has signed three groundbreaking agreements that aim to support the use of 500,000 acres of tribal farmland for cannabis cultivation in a move that the Alliance says will provide economic sovereignty to indigenous farmers.
Native American Cannabis Alliance (NACA), a joint venture of Tim Houseberg, the executive director of Cherokee Nation-based Native Health Matters Foundation, and Everscore, the first direct-to-consumer marketplace for THC and CBD products, has signed three memorandums of understanding (MoU) with indigenous farmers from tribes such as Mohawk Nation, Cheyenne and Arapaho Tribal Nations.
These agreements will support the use of tribal farmland for cannabis farming with agricultural services, the development of manufacturing campuses to process cannabis grown the land, workforce development, and access to offtake agreements by brands selling on the Everscore online marketplace.
Houseberg commented: “Our people come from a rich heritage of cultivation and the cannabis industry provides an historical opportunity for First Nations to work together to shape the future of the industry and provide sovereignty to our communities.
“Through NACA, indigenous farmers will be known worldwide for their quality products by brands and consumers alike.”
“The cannabis industry is experiencing explosive growth and is expected to be a $100 billion-dollar industry by 2030, but the opportunity is not shared equally,” said Jeffrey Sampson, CEO and Founder of Everscore.
“We use modern technology to bridge the fragmented supply chain and create a more collaborative, sustainable ecosystem while benefitting indigenous communities. Brands selling on Everscore will now have a one-stop option for high-quality supply built on transparency.”
Nathan Hart, Secretary of Agriculture, Cheyenne and Arapaho Tribes, added: “The core of our agriculture operations is the health of our soils.
“We believe in a relationship where we take care of the soils, healthy soils produce healthy vegetation which produces healthy products for human consumption. We desire that our hemp programme be involved in educating others from the producers, to the processors, to the end consumers. This system of reciprocity is a core value we greatly respect.”
“As many of our traditions, cultivation has been passed down from generation to generation,” said Roger Jock, representative of the Mohawk Bear Clan people. “NACA is operated in the spirit of the tribal alliances formed hundreds of years ago with the benefit of modern technology.
“We invite our fellow tribes to explore joining NACA to activate the next generation of indigenous farmers and secure sovereignty for all.”
- Life sciences company to expand into medical cannabis market
- European Medicines Agency gives cannabinoid medicine positive opinion
- Cannabis regulation changes across Switzerland and Luxembourg
- Cannabis investment company to see UK and Europe growth
- How COVID has and will continue to change the cannabis market